Beth C Seidenberg sold $720k of VERA
director at Vera Therapeutics, Inc.. 15,000 shares at an average of $48.03, traded Oct 28, 2024, filed Oct 30, 2024.
Score components
- +15RoleDirector
- +21Trade size$720k at market
- +5Share of holdings soldSold 10% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +22.4%, 3m -6.7%, 6m -42.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-025746, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 28, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -14,798 | $48.01 | $710k | 131,755 | Oct 30, 2024 |
| Oct 28, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -202 | $49.54 | $10k | 131,553 | Oct 30, 2024 |
Related signals
Other insiders at Vera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $685k 18,500 shares | -7% | |
| 10Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $650k 18,500 shares | -7% | |
| 39Weak | Vera Therapeutics, Inc. | Robert Brenner Chief Medical Officer | $90k 2,151 shares | -4% | |
| 61Notable | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $711k 16,925 shares | -6% | |
| 49Moderate | Vera Therapeutics, Inc. | Sean Grant CHIEF FINANCIAL OFFICER | $208k 4,949 shares | -4% | |
| 8Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $501k 10,000 shares | -31% | |
| 36Weak | VERAbuy Vera Therapeutics, Inc. | Patrick G Enright director | $250k 5,882 shares | - | |
| 7Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $453k 10,000 shares | -31% | |
| 14Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $400k 10,000 shares | -31% | |
| 40Moderate | Vera Therapeutics, Inc. | Jason S Carter Chief Legal Officer | $107k 3,864 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.